Regression of leukemia cutis with gilteritinib in a case of FLT3-positive acute myeloid leukemia

Abstract

Acute myeloid leukemia is a hematological disease with a poor prognosis. Blast cells that characterize the disease are generally present in the bone marrow, but they can sometimes be located in different organs. This rare event can occur at diagnosis or at relapse, together or not with bone marrow involvement, and worsens prognosis and management. Despite this, the introduction into clinical practice of newly approved drugs directed towards molecular targets and approved for acute myeloid leukemia will pave the way for new treatment approaches facing this rare disease. In this paper, we present a case of a patient with acute myeloid leukemia with extramedullary manifestations involving the cutis and responding to FLT3-directed target therapy.

Keywords

• AML
• Myeloid sarcoma
• FLT3
• FLT3-inhibitors
• Extramedullary AML